OTTMUSG00000016694 Inhibitors

Ferritin, heavy polypeptide-like 17-like 3 (Fthl17d) plays a vital role in iron storage and regulation within cells. To inhibit the functionality of Fthl17d, a diverse range of chemical inhibitors has been identified, each with distinct mechanisms of action. Deferoxamine, for instance, acts as a direct inhibitor by chelating iron ions, effectively sequestering them and rendering them unavailable for utilization by Fthl17d. This inhibition prevents the protein from fulfilling its essential function of iron storage and regulation within the cell, ultimately leading to functional inhibition. Another chemical inhibitor, Gallium Nitrate, indirectly inhibits Fthl17d by interfering with iron uptake pathways. By disrupting these pathways, Gallium Nitrate reduces the availability of iron ions for Fthl17d's utilization. This indirect inhibition hinders the protein's ability to maintain proper iron balance within the cell. Dipyridyl, on the other hand, operates similarly to Deferoxamine, acting as a direct inhibitor through iron chelation. It competes with Fthl17d for iron ions, preventing the protein from effectively performing its iron storage function.

Furthermore, Bortezomib targets the NF-κB pathway, indirectly influencing Fthl17d regulation. This pathway is crucial for the protein's expression and activity, and Bortezomib's action disrupts it, leading to functional inhibition of Fthl17d. Deferasirox, another inhibitor, interferes with Fthl17d's iron metabolism indirectly. By chelating iron ions and modulating iron-related pathways, Deferasirox reduces the protein's ability to effectively manage iron balance. Actinomycin D downregulates Fthl17d mRNA expression, directly impacting protein production and leading to its functional inhibition. L-mimosine, while indirect, modulates iron metabolism pathways, influencing Fthl17d's iron regulation function. Apotransferrin disrupts Fthl17d's iron-binding capacity, effectively rendering the protein incapable of proper iron storage. SB-431542, targeting the BMP-SMAD pathway, indirectly inhibits Fthl17d through downstream signaling effects, impacting the protein's function. Ferristatin II competitively binds to Fthl17d's iron substrate, effectively preventing its utilization and functional inhibition of the protein. CPX-351 (Vyxeos) directly interferes with Fthl17d's iron-handling capabilities, disrupting its role in iron regulation. Lastly, Deferiprone hampers Fthl17d's iron transport mechanism, inhibiting its iron-binding capacity and contributing to functional inhibition. These chemical inhibitors provide valuable tools for researchers to explore the intricacies of Fthl17d's role in iron regulation and cellular processes, shedding light on the broader implications of its inhibition within the cell.